Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Nktr save search
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
Published: 2023-10-13 (Crawled : 12:30) - prnewswire.com
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: 3.39%
H: 1.63%
C: -0.37%
t-cell congress presentation
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -2.01%
H: 4.52%
C: -2.35%
t-cell congress therapeutics therapy
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
Published: 2023-04-27 (Crawled : 13:20) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: 0.26%
H: 1.82%
C: -2.21%
nktr-358 t-cell therapeutics therapy
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
Published: 2022-11-09 (Crawled : 14:20) - biospace.com/
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -0.79%
H: 0.66%
C: -4.79%
nktr-255 blood preclinical immunotherapy car-t publication
Regulatory T-cells (Tregs) Therapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot
Published: 2022-02-16 (Crawled : 08:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.52%
H: 1.83%
C: 1.24%
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.36%
trial cel t-cell therapy
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
Published: 2021-12-28 (Crawled : 06:00) - globenewswire.com
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -0.91%
H: 1.18%
C: -1.31%
therapeutics cel sars-cov-2 vaccine t-cell
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity
Published: 2021-05-20 (Crawled : 15:15) - prnewswire.com
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -1.46%
H: 2.53%
C: -0.22%
autoimmunity expansion designation
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
Published: 2020-12-15 (Crawled : 16:00) - biospace.com/
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: 1.25%
H: 3.5%
C: 3.19%
cancer colorectal cancer phase 3 phase 1 phase 2 cell carcinoma
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.